Jeremy S. Myers

Resolve Therapeutics (United States) — United States

Medicine · Health Sciences

23h-index3.9kcitations66works0.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(24), HER2/EGFR in Cancer Research(19), CAR-T cell therapy research(14), Epigenetics and DNA Methylation(8), Genomics and Phylogenetic Studies(7)

Publications66 total

EVOLVE platform, a trispecific T cell engager with integrated CD2 costimulation, for the treatment of solid and hematologic tumors
Proceedings of the National Academy of Sciences·2025· 1 citedOpen Access
Abstract 3519: EVOLVE104, a differentiated T cell engager targeting the novel antigen ULBP2/5/6, exhibits potent preclinical efficacy for the treatment of squamous tumors
Cancer Research·2025
Abstract 2137: EVOLVE205, a dual (2:1) CD20 targeted CD3 trispecific T cell engager with CD2 costimulation for the treatment of B cell malignancies and B cell autoimmune disorders
Cancer Research·2025
EVOLVE205, a Highly Potent 2:1 CD20-Targeted CD2 Co-Stimulatory T Cell Engager Engineered for the Treatment of B Cell Malignancies and B Cell Autoimmune Diseases
Blood·2024· 3 citedOpen Access
1137 EVOLVE205, a highly potent 2:1 CD20-targeted CD2 co-stimulatory T cell engager engineered for the treatment of B cell malignancies and B cell autoimmune diseases
Regular and Young Investigator Award Abstracts·2024Open Access
1326 Precision oncology strategy for EVOLVE104, a differentiated T cell engager for the novel solid tumor target ULBP2/5/6
Regular and Young Investigator Award Abstracts·2024Open Access
1339 EVOLVE104, a first-in-class ULBP2/5/6-targeting T-cell engager with integrated CD2 co-stimulation, demonstrates a favorable preclinical safety and toxicity profile in cynomolgus monkeys
Regular and Young Investigator Award Abstracts·2024Open Access
Abstract 2369: EVOLVE-105, a differentiated CD20-targeted CD2 co-stimulatory T cell engager engineered for the treatment of B cell malignancies
Cancer Research·2024
VEuPathDB: the eukaryotic pathogen, vector and host bioinformatics resource center in 2023
Nucleic Acids Research·2023· 217 citedOpen Access
1392 EVOLVE-104, a novel ULBP2-targeted T cell engager that integrates CD2 costimulation for the treatment of basal and squamous lineage tumors
Regular and Young Investigator Award Abstracts·2023· 1 citedOpen Access
1386 EVOLVE-106, a T cell engager with integrated CD2 costimulation targeting B7-H4, is a precision therapy for estrogen and Her2 receptor low breast cancers
Regular and Young Investigator Award Abstracts·2023· 2 citedOpen Access
Abstract 4094: Enhanced CRISPR-Cas9 edited CAR-T cells through simultaneous inactivation of multiple T cell exhaustion pathways
Cancer Research·2023· 1 cited
Abstract 2971: EVOLVETM: A novel T cell engager platform with integrated CD2 costimulation engineered for the treatment of immune suppressive tumors
Cancer Research·2023· 3 cited
Supplementary Methods, Figures S1-S10, and Table S1 from Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1)
2023Open Access
Data from Tumor Cells Chronically Treated with a Trastuzumab–Maytansinoid Antibody–Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments
2023Open Access
Supplementary Figures S1 to S11 from Tumor Cells Chronically Treated with a Trastuzumab–Maytansinoid Antibody–Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments
2023Open Access
Data from Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1)
2023Open Access
Supplementary Methods, Figures S1-S10, and Table S1 from Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1)
2023Open Access
Supplementary Figures S1 to S11 from Tumor Cells Chronically Treated with a Trastuzumab–Maytansinoid Antibody–Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments
2023Open Access
Data from Tumor Cells Chronically Treated with a Trastuzumab–Maytansinoid Antibody–Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Judy Lucas(15), Guixian Jin(12), Hans‐Peter Gerber(12), Frank Loganzo(11), Xingzhi Tan(11), Edward Rosfjord(11), Kim Arndt(8), Wenyan Zhong(8), Mark A. Batzer(7), Matthew Sung(7), Sylvia Musto(7), Hayden Karp(7), Louis Matis(7), Oksana A. Sergeeva(7), Russell G. Dushin(6), Maximillian T. Follettie(6), My‐Hanh Lam(6), Kiran Khandke(6), Bingwen Lu(6), Justin Lucas(6)